Evidence map›Paper›PMID 41305932›Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

Restoring Muribaculum intestinale-Derived Butyrate Mitigates Skeletal Muscle Loss in Cancer Cachexia.

Li Li, Panpan Lian, Wei Dong, Shiyu Song, Junaid Wazir, Ranran Wang, Kai Lin, Wenyuan Pu, Renwei Lu, Zhenghong Yu and 4 more

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in microbiology · 2026
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Li LiState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Panpan LianState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Wei DongState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Shiyu SongState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Junaid WazirState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Ranran WangState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Kai LinState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Wenyuan PuState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Renwei LuState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Zhenghong YuDepartment of Rheumatology and Immunology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Chao DingDepartment of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhiqiang HuangState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Yong WangState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.
Hongwei WangState Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, P. R. China.ORCID 0000-0003-2868-5112

Funding

Fundamental Research Funds for the Central Universities 0214/14380538Fundamental Research Funds for the Central Universities 0214/14380550Jiangsu Province Basic Research Fund BK20251988Nanjing University 0214/14912217Nanjing University Laboratory Safety Research Fund LSK202402National Key Research and Development Program of China 2022YFF0710801National Key Research and Development Program of China 2023YFC0872300National Natural Science Foundation of China 82070912National Natural Science Foundation of China 82370899National Natural Science Foundation of China 82571040
6 · The paper itself

Abstract

backgroundMuscle wasting in cancer cachexia patients is a major clinical challenge. Although reduced levels of short-chain fatty acids (SCFAs) in cachexia patients have been associated with muscle atrophy, their precise role remains unclear. Given that the gut microbiota is the primary source of SCFAs, modulating SCFA composition through probiotic supplementation has shown promise in preclinical studies of cancer cachexia. In this study, we aimed to elucidate the dysregulation of the gut microbiota in cachexia mice and investigate the potential protective effect of supplementation with the inulin diet, Muribaculum intestinale (MI) and sodium butyrate (NaB) against cachexia-induced muscle wasting.

methodsWe analysed the gut microbiota composition using 16S rRNA gene amplicon sequencing and measured SCFA levels to evaluate metabolic changes in faecal samples from cancer cachexia models. We identified the associations between the microbiota and metabolites and evaluated the impacts of MI (10

resultsFaecal analysis in cachectic mice revealed a significant alteration in gut microbiota composition, particularly a reduction in Muribaculaceae (76.0%) and Muribaculum intestinale (82.0%). Direct supplementation with MI increased its abundance and butyrate level (p < 0.05), reducing muscle wasting in cachexia. Correlation analysis underscored a significant positive association between Muribaculaceae, Muribaculum intestinale and butyrate levels (p < 0.05). NaB also ameliorated muscle wasting, with RNA-Seq of muscle tissues showing a decrease in inflammatory factors and autophagy, downregulation of pyruvate dehydrogenase kinase 4 (Pdk4) expression (61.6%) and increased ATP content (25.5%), thereby playing a pivotal role in attenuating muscle degradation in cancer cachexia. Supplementation with inulin diet increased the levels of Muribaculaceae and Muribaculum intestinale (p < 0.05), also alleviating cachexia symptoms in mice.

conclusionsIn cachectic mouse models, Muribaculaceae and Muribaculum intestinale are reduced and exhibit a significant positive correlation with SCFA butyrate. Inulin or MI supplementation increased these bacteria, ameliorating cachexia. NaB attenuates muscle wasting through coordinated modulation of autophagy suppression, anti-inflammatory effects and metabolic reprogramming (including PDK4 downregulation and ATP elevation), collectively indicating the existence of a gut-muscle axis in cachexia progression. These findings underscore the potential of microbiota-targeted interventions in managing cancer cachexia and highlight the intricate interplay between gut microbiota and skeletal muscle health.

Indexed as

ButyratesCachexiaMuscle, SkeletalMuscular AtrophyNeoplasmsAnimalsButyric AcidDisease Models, AnimalFatty Acids, VolatileGastrointestinal MicrobiomeHumansMaleMiceButyratesButyric AcidFatty Acids, Volatilecancer cachexiagut microbiotaMuribaculaceaeMuribaculum intestinalemuscle atrophyshort‐chain fatty acid

Identifiers

PMID41305932
PMCPMC12657623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.